Friday 21 June 2024

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox